Importance of neoadjuvant chemotherapy in olfactory neuroblastoma treatment: Series report and literature review

Bartel, Ricardo; Gonzàlez-Compta, Xavier; Cisa, Enric; Cruellas, Francesc; Torres, Alberto; Rovira, Aleix; Mañós, M.

doi:10.1016/j.otoeng.2017.07.003

Cited by 5 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current treatment strategy in adults includes surgery followed by radiation therapy . Chemotherapy might be used in case of high‐grade, recurrent, or locoregionally advanced tumors . In pediatric cases, chemotherapy combined with surgery and radiotherapy (RT) is often the treatment of choice in advanced diseases compared to adult ones .…”

Section: Introductionmentioning

confidence: 99%

“…[12][13][14][15][16] Chemotherapy might be used in case of high-grade, recurrent, or locoregionally advanced tumors. [17][18][19] In pediatric cases, chemotherapy combined with surgery and radiotherapy (RT) is often the treatment of choice in advanced diseases compared to adult ones. 3,6 The incidence of cervical node metastases is about 10% at diagnosis but can increase to 20% during the disease in adults.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Pattern of loco‐regional relapses and treatment in pediatric esthesioneuroblastoma: The French very rare tumors group (Fracture) contribution

Dumont

Fresneau

Claude

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background Esthesioneuroblastoma (ENB) is a rare neuroectodermal tumor that seldom occurs during childhood. Multimodal treatments are currently proposed, but the place of each therapy is still in debate. Our objective is to describe clinical evolution, especially the pattern of relapses and determine contributors to tumor progression. Procedure Medical charts of all children (≤18 years) affected by ENB treated in France from January 1990 to December 2015 were retrospectively analyzed. Results Eighteen patients were selected (10 males). Median age at diagnosis was 12.2 years (0.9‐18). Tumor extension was Kadish stage A (n = 1), B (n = 3), C (n = 10), and D (n = 4). Hyams histological grades were I (n = 1), II (n = 3), III (n = 6), and IV (n = 6) (in two cases not defined). Initial cervical nodal spread was assessed by magnetic resonance imaging (n = 15), computed tomography scan (n = 16), fluorodeoxyglucose‐positron emission tomography‐computed tomography (n = 7), and cytological/histological analysis (n = 2). N1 stage was confirmed by imaging in two of 18 cases and one of two cases had cervical node dissection with neck irradiation (58 Gy). After a median follow‐up of survivors of 7.6 years (3.8‐17.9), 10 patients developed neuromeningeal progression, whereas no cervical nodal relapse occurred and only eight survived. Both 5‐year overall and event‐free survival rates were 44.4% (±11.7%). Conclusions The poor prognosis is mainly related to neuromeningeal dissemination that should be considered during treatment strategy. However, cervical lymph node relapse is rare.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Pattern of loco‐regional relapses and treatment in pediatric esthesioneuroblastoma: The French very rare tumors group (Fracture) contribution

Dumont

Fresneau

Claude

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Bartel et al. ( 8 ) conducted a retrospective study of nine patients with ONB of the nasal cavity and paranasal sinuses (six patients at Kadish stage C) and concluded that induction chemotherapy played an important role in reducing tumor size, obtaining safe resection margins, and minimizing complications. The MD Anderson Cancer Center treated 15 patients with ONB of the nasal cavity and paranasal sinuses (including 12 patients at stage T4) with induction chemotherapy followed by radical treatment (radical radiotherapy, surgery, and concurrent chemoradiotherapy) and achieved 5-year total DFS and total OS rates of 71% and 78%, respectively.…”

Section: Discussionmentioning

confidence: 99%

Multimodal Treatment With Orbital Organ Preservation in Adult Patients With Locally Advanced Small-Round-Cell Malignancy of the Nasal Cavity and Paranasal Sinus

Nan-xiang

Fan

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundTo investigate the efficacy of induction chemotherapy followed by concurrent chemotherapy and helical tomotherapy in adult patients with locally advanced small-round-cell malignancy of the nasal cavity and paranasal sinus in regard to orbital organ preservation and quality of life.MethodsThe clinical data of 49 patients with orbital involvement of locally advanced small-round-cell malignancy of the nasal cavity and paranasal sinus who received multimodal treatment for orbital organ preservation between December 2009 and January 2019 were retrospectively analyzed. Treatment efficacy and side effects were assessed. The study included three different pathological types. All patients were treated with induction chemotherapy followed by concurrent chemoradiotherapy. Helical tomotherapy was applied as radiotherapy. Adverse reactions to the chemotherapy were assessed according to Common Terminology Criteria for Adverse Events, Version 3. The overall survival (OS) rate, progression-free survival (PFS) rate, and orbital preservation rate were calculated using the Kaplan-Meier method.ResultsAfter multimodal treatment, the 3- and 5-year OS rates of the 49 patients were 63.8% and 54.5%, respectively, and the 3- and 5-year total PFS rates were 66.8% and 63.1%, respectively.ConclusionsMultimodal treatment can preserve the orbital organs of adult patients with small-round-cell malignancy of the nasal cavity and paranasal sinus, achieve relatively ideal organ protection and survival rates, and improve quality of life, thus providing a new treatment option for these patients.

show abstract

“…In cases of regional invasion and distant metastasis, chemotherapy can improve the quality of life and extend survival time. [ 19 ] In this case we reported here, extensive bone infiltration made us chose the cyclophosphamide and pirarubicin (CA) regime for chemotherapy. After continuous chemotherapy, the complete blood cell counts gradually recovered and the tumor growth was inhibited, which indicated that CA regime is valid to treat ONB.…”

Section: Discussionmentioning

confidence: 99%

Occult olfactory neuroblastoma presenting with multiple bone metastases: a case report

Zhou

Liu

et al. 2020

Medicine

View full text Add to dashboard Cite

Rationable: Olfactory neuroblastoma (ONB) is a rare malignant tumor of the nasal cavity, the primary local symptoms are usually inconspicuous. Patients are often admitted to various specialties based on different primary symptoms, which may result in delayed diagnosis and even a misdiagnosis. Patient concerns: Here we report a case of ONB that presented initially as multiple ostealgia without any local symptoms of the tumor and primarily misdiagnosed as multiple myeloma. The patient was a 47-year-old female with bone pain at multiple sites. The initial diagnosis was considered as multiple myeloma. However, the morphologic examination of bone marrow suggested that the tumor cells originated from the nervous tissues. After the positron emission computed tomography scan, the primary lesion in the nasal cavity was located, and a biopsy was performed. Diagnosis: The final diagnosis of ONB was confirmed by histopathological tests. Interventions: The patient was treated with metronomic chemotherapy. Outcomes: The symptoms of bone pain were significantly relieved 3 months later. The emission computed tomography scan of the whole body bones and the magnetic resonance imaging of the head showed that the tumor size did not change significantly and proved a progression-free of the disease. Lessons: It is a reasonable strategy to identify the original latent tumor by a prompt positron emission computed tomography scan when the primary diagnosis indicates a metastatic disease, especially for the occult malignancies like ONB.

show abstract

Importance of neoadjuvant chemotherapy in olfactory neuroblastoma treatment: Series report and literature review

Cited by 5 publications

References 35 publications

Pattern of loco‐regional relapses and treatment in pediatric esthesioneuroblastoma: The French very rare tumors group (Fracture) contribution

Pattern of loco‐regional relapses and treatment in pediatric esthesioneuroblastoma: The French very rare tumors group (Fracture) contribution

Multimodal Treatment With Orbital Organ Preservation in Adult Patients With Locally Advanced Small-Round-Cell Malignancy of the Nasal Cavity and Paranasal Sinus

Occult olfactory neuroblastoma presenting with multiple bone metastases: a case report

Contact Info

Product

Resources

About